{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:25:24Z","timestamp":1762151124094,"version":"build-2065373602"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021828","name":"German Academic Exchange Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021828","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      CD137 (4-1BB), a member of the tumour necrosis factor (TNF) receptor superfamily, plays a key role in T-cell activation, survival, and cytokine production, functions that are central to immune responses against\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      . This scoping review brings together current evidence on the clinical relevance of CD137 in tuberculosis (TB), including its potential as a diagnostic, prognostic, and therapeutic target.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR). Relevant studies on CD137 in TB were identified through database searches and screened using predefined eligibility criteria. Experimental, animal, and human studies reporting on CD137 expression, function, or clinical associations were included. Key information from each study was charted to describe the scope, characteristics, and main findings of the available evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified ten eligible studies involving\n                      <jats:italic>in vitro<\/jats:italic>\n                      experiments, animal models, and human cohorts. CD137-positive T cells and soluble CD137 (sCD137) levels were consistently elevated in active TB, with some evidence suggesting the ability to distinguish disease states and predict severity. Mechanistic studies show that CD137 modulates cytokine responses, including interferon-gamma (IFN-\u03b3) and TNF-\u03b1, and interacts with other immune checkpoints such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Preclinical models have demonstrated that CD137-targeted strategies may enhance mycobacterial control. Although current findings are promising, most studies are small, geographically limited, and exploratory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>CD137 remains an underexplored immune checkpoint with potential to inform host-directed TB diagnostics and therapies, offering a new angle for precision immunology in high-burden settings. Large-scale, longitudinal studies are needed to define its role in host immunity and determine its translational value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1682269","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:22:50Z","timestamp":1762150970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Nuraddin","family":"Nasir Goronyo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bih H.","family":"Chendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalena","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novel N.","family":"Chegou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","volume-title":"Global Tuberculosis Report","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2386030","DOI":"10.1080\/07853890.2024.2386030","article-title":"Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review","volume":"56","author":"Leo","year":"2024","journal-title":"Ann Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.899900","article-title":"Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis","volume":"12","author":"Norbis","year":"2014","journal-title":"Expert Rev anti-infective Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/1040841X.2016.1262813","article-title":"Diagnosis and treatment of paediatric tuberculosis: an insight review","volume":"43","author":"Mandal","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.92630","article-title":"Diagnosis & treatment of tuberculosis in HIV co-infected patients","volume":"134","author":"Padmapriyadarsini","year":"2011","journal-title":"IJMR"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.709793","article-title":"Past and present approaches to diagnosis of active pulmonary tuberculosis","volume":"8","author":"Namuganga","year":"2021","journal-title":"Front Med"},{"key":"B7","article-title":"Tuberculosis diagnosis: updates and challenges","volume-title":"Bacterial Infectious Diseases Annual","author":"Shivakumar","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12879-022-07287-5","article-title":"Diagnostic performance of GeneXpert MTB\/RIF in detecting MTB in smear-negative presumptive TB patients","volume":"22","author":"Rimal","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.9745\/GHSP-D-12-00004","article-title":"GeneXpert for TB diagnosis: planned and purposeful implementation","volume":"1","author":"Piatek","year":"2013","journal-title":"Global Health: Sci Practice"},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tube.2016.06.001","article-title":"Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection","volume":"102","author":"Wu","year":"2017","journal-title":"Tuberculosis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00151413","article-title":"Beyond the IFN-\u03b3 horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis","volume":"43","author":"Chegou","year":"2014","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Kahwati","year":"2016","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02006","article-title":"Diagnosis for latent tuberculosis infection: new alternatives","volume":"11","author":"Carranza","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"a018424","DOI":"10.1101\/cshperspect.a018424","article-title":"Innate and adaptive cellular immune responses to Mycobacterium tuberculosis infection","volume":"5","author":"Mayer-Barber","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tube.2010.08.007","article-title":"Optimization of inhaled therapies for tuberculosis: the role of macrophages and dendritic cells","volume":"91","author":"Gonz\u00e1lez-Juarrero","year":"2011","journal-title":"Tuberculosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12274","article-title":"T cells and adaptive immunity to Mycobacterium tuberculosis in humans","volume":"264","author":"Jasenosky","year":"2015","journal-title":"Immunol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0025-3","article-title":"Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection","volume":"18","author":"Simmons","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cancers13102288","article-title":"CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development","volume":"13","author":"Hashimoto","year":"2021","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350796","article-title":"The levels of soluble CD137 are increased in tuberculosis patients and associated with disease severity and prognosis","volume":"54","author":"Yi","year":"2024","journal-title":"Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.imbio.2013.08.009","article-title":"Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection","volume":"219","author":"Mart\u00ednez G\u00f3mez","year":"2014","journal-title":"Immunobiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-5748(99)00095-7","article-title":"Role of fibroblast growth factor-2 in human brain: a focus on development","volume":"18","author":"Gremo","year":"2000","journal-title":"Int J Dev Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.7.3360","article-title":"Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28","volume":"155","author":"Hurtado","year":"1995","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2338","article-title":"Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen","volume":"164","author":"Rogers","year":"2000","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.4882","article-title":"4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1","volume":"169","author":"Lee","year":"2002","journal-title":"J Immunol"},{"key":"B25","article-title":"Immunotherapy with agonistic anti-CD137: two sides of a coin","volume":"1","author":"Sun","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","article-title":"Immune regulation by 4-1BB and 4-1BBL: complexities and challenges","volume":"229","author":"Wang","year":"2009","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1078-0432.CCR-13-2573","article-title":"CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert","volume":"20","author":"Zhu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2326-6066.CIR-17-0767","article-title":"Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation","volume":"6","author":"Teijeira","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.63","article-title":"CD137 differentially regulates innate and adaptive immunity against Mycobacterium tuberculosis","volume":"90","author":"Fern\u00e1ndez Do Porto","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2003.08.012","article-title":"Inhibition of cytokines expression in human microglia infected by virulent and non-virulent mycobacteria","volume":"44","author":"Curto","year":"2004","journal-title":"Neurochem Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2741\/3521","article-title":"CD137, implications in immunity and potential for therapy","volume":"14","author":"Thum","year":"2009","journal-title":"Front Biosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.771809","article-title":"CD137 agonists targeting CD137-mediated negative regulation show enhanced antitumor efficacy in lung cancer","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/cancers16020268","article-title":"Shift in tissue-specific immune niches and CD137 expression in tuberculoma of pembrolizumab-treated nasopharyngeal carcinoma patients","volume":"16","author":"Kam","year":"2024","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ymthe.2024.12.010","article-title":"CD137-expressing regulatory T cells in cancer and autoimmune diseases","volume":"33","author":"Lee","year":"2025","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-019-0386-4","article-title":"CD137 expression in cancer cells: regulation and significance","volume":"39","author":"Glorieux","year":"2019","journal-title":"Cancer Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12541","article-title":"CD137 is a useful marker for identifying CD4(+) T cell responses to mycobacterium tuberculosis","volume":"85","author":"Yan","year":"2017","journal-title":"Scand J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cellimm.2018.03.013","article-title":"4-1BB expression on MAIT cells is associated with enhanced IFN-\u03b3 production and depends on IL-2","volume":"328","author":"Jiang","year":"2018","journal-title":"Cell Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"110331","DOI":"10.1016\/j.clim.2024.110331","article-title":"CD137 expression and signal function drive pleiotropic \u03b3\u03b4 T-cell effector functions that inhibit intracellular M. tuberculosis growth","volume":"266","author":"Ji","year":"2024","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055987","article-title":"Bayesian approach to model CD137 signaling in human M. tuberculosis in vitro responses","volume":"8","author":"Fern\u00e1ndez Do Porto","year":"2013","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e11019","DOI":"10.1371\/journal.pone.0011019","article-title":"Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells","volume":"5","author":"Palma","year":"2010","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1398403","article-title":"The predictive value of TNF family for pulmonary tuberculosis: a pooled causal effect analysis of multiple datasets","volume":"15","author":"Mo","year":"2024","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.608846","article-title":"A plasma 5-marker host biosignature identifies tuberculosis in high and low endemic countries","volume":"12","author":"Chendi","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207999","article-title":"Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB","volume":"71","author":"Chegou","year":"2016","journal-title":"Thorax"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1682269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:22:51Z","timestamp":1762150971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1682269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2025.1682269"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1682269","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1682269"}}